Market Closed -
Other stock markets
|
Pre-market 09:07:53 am | |||
75.03 USD | +5.38% | 75.13 | +0.13% |
10:34am | Peel Hunt cuts ConvaTec to 'reduce' | AN |
10:23am | THE FTSE 100 is on a roll |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.40% | 233B | - | ||
+24.67% | 556B | B | ||
-6.33% | 354B | C+ | ||
+19.90% | 331B | B- | ||
+7.95% | 296B | C+ | ||
+5.44% | 201B | B- | ||
-9.98% | 193B | A+ | ||
-12.26% | 143B | C+ | ||
-6.47% | 144B | C+ | ||
+1.26% | 123B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AZN Stock
- AZN Stock
- Ratings AstraZeneca PLC